FotoFinder Systems: Artificial Intelligence Revolutionizes Skin Cancer Detection
"Artificial Intelligence" (AI) is currently on everyone's lips. Experts say companies need to focus on three aspects of AI to play a leading role in the topic: latest programming insights, importance of data and AI integration into existing workflows. FotoFinder Systems already combines these key aspects today. As a pioneer, the high-tech company is a leader in integrating AI into technology for skin cancer diagnostics. With the new expert software Moleanalyzer pro, dermatologists are able to assess moles with AI. Validation results confirm an extremely high accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005031/en/
Artificial Intelligence in skin cancer detection (Copyright tiler84, iStock)
High-tech meets specialist expertise
Moleanalyzer pro offers physicians the possibility to confirm their diagnosis with various evaluation techniques. For the first time, it is possible to combine specialist expertise with AI and additionally to receive a second opinion – per mouse click – from renowned international skin cancer experts.
AI in dermoscopy
Moleanalyzer pro works with deep learning: The human ability to learn from examples and experiences was transferred to the computer. For this purpose the “Convolutional Neural Network” (CNN) was trained with the currently largest data collection of dermoscopic images including corresponding diagnosis. Due to many years of valuable cooperation with physicians worldwide, the continuous "feeding" of the algorithm succeeds. With growing experience and its own autonomous rules, it is able to distinguish between benign and malignant lesions. The result is a score that supports the risk assessment of both melanocytic and non-melanocytic skin lesions. Shortly, this AI Score will be available for doctors also on mobile devices.
Validated, precise, self-learning
According to the representative study "Man against machine"*, the deep learning algorithm showed an impressively high sensitivity by correctly identifying 95% of malignant skin tumors. In the comparison group, the experts – 58 dermatologists from 17 nations – identified 86.6% of the lesions as malignant. The algorithm also showed a reliably high specificity by identifying 82.5% of benign nevi correctly, while the experts identified 71.3% as benign.
Artificial Intelligence meets human experience
As fascinating as AI is, it cannot replace human experience in the matter of skin cancer. In the end, the doctor decides what to do. In case of doubt, Moleanalyzer pro offers a second opinion service from internationally renowned skin cancer specialists to confirm the diagnosis.
About FotoFinder Systems
Founded in 1991 the German company is specialized in skin cancer diagnostics by means of Automated Total Body Mapping, digital dermoscopy, in hair diagnostics, psoriasis documentation and imaging in aesthetics. Subsidiaries in Italy, Spain, UK and the U.S. and a global partner network support the company’s worldwide presence. FotoFinder won the Bavarian Export Award, Red Dot Design Award and was honored as one of the most innovative companies in Lower Bavaria.
* "Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists", by H.A. Haenssle et al. Annals of Oncology. doi:10.1093/annonc/mdy166
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism26.3.2019 18:01:00 EET | Tiedote
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-term risks of renal and cardiovascular complications that patients treated with conventional therapy may experience. Six-year results from the open-label long-term safety and efficacy RACE study were also announced. Data was presented at the Endocrine Society’s 2019 Annual Meeting (ENDO) from 23–26 March in New Orleans, Louisiana, USA. “Results from the Burden of Illness Global Survey in 13 countries reveal the extent of the impact hypoparathyroidism has on patients and their caregivers throughout their daily lives,” said John Bilezikian M.D., Professor of Medicine at the Columbia University Irving Medical Center, New York, NY, USA. “This offers important insights and enables us to take a more holistic approach in the management of these patients due to a greater understanding of the poten
LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development26.3.2019 17:58:00 EET | Tiedote
Veeva Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader in medical dermatology, selected Veeva Development Cloud applications to help drive end-to-end business processes across product development. The company will utilize the Vault Clinical, Vault RIM, and Vault Quality suites to unify drug development on a single cloud platform. With Veeva Development Cloud, LEO Pharma can bring together applications for clinical, regulatory, and quality for even greater efficiency and compliance throughout the product development lifecycle. “LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline,” said Kim Kjøller, executive vice president of global research and development at LEO Pharma. “Veeva Development Cloud gives us a unified platform that can enable us to maximize eff
Keio Plaza Hotel Tokyo Hosts Japanese Sword Culture, Armor Exhibition – “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans”26.3.2019 17:05:00 EET | Tiedote
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host a special exhibition entitled “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans” displaying beautiful Japanese swords and armor from April 25 (Thursday) to June 27 (Thursday), 2019 in the 3rd floor lobby of our Hotel. This exhibition is part of our series of cultural programs designed to introduce various aspects of Japanese culture to our guests visiting the Hotel from over 100 different countries around the world. Various precious and old swords and armor made during the Heian Period (794-1185) and other periods of Japanese history will be displayed, along with “tsuba” (Sword handle guards separating the handle from the blade) and other ornate sword fittings. On May 14, two masters of sword-drawing from Ryushin Shouchi School will give a live performance in the Main lobby from 5:00 p.m. This press release features multimedia. View the full release
Andersen Global Enters Qatar26.3.2019 16:30:00 EET | Tiedote
Andersen Global today announced a collaborating agreement in Qatar with Al-Khalifa Law, a leading Doha-based law firm. The collaboration is Andersen Global’s first in Qatar and is part of the organization’s continued growth in the Middle East. Al-Khalifa Law was founded 20 years ago and established itself as a premier firm in the region. The team at Al-Khalifa Law has diversified, deep experience providing services in a wide variety of business sectors, such as commercial contracts, taxation, employment, real estate and retail, intellectual property, dispute resolution and litigation and arbitration. “A collaboration with Andersen Global, which brings with it a culture of stewardship, transparency, and providing best-in-class services, was an obvious decision for us,” said Hamzeh Abdelhady, Office Managing Director of Al-Khalifa Law. “We will be able to continue providing quality services in the market and bring a premier, seamless association of experts throughout the world directly t
Vivior’s System Cleared for CE Mark – Market Introduction This Year in Europe26.3.2019 16:18:00 EET | Tiedote
Vivior has cleared their system as a Class I medical device and is planning the market introduction later this year in Switzerland and the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005594/en/ The Visual Behavior Monitor (Photo: Business Wire) Vivior has notified Swissmedic about their product, the Visual Behavior Monitor, and fulfills all requirements for a medical device Class I according to the Medical Device Directive (MDD). With this important step, Vivior is now allowed to sell their system in Switzerland and the European Union. Mario Stark, CEO at Vivior, explains: “We are happy to be able to start market introduction and will, in a first step, work with selected clinics in Europe.” Prof. Michael Mrochen, Chairman of the Board of Directors, adds: “This constitutes an important milestone in the development of the Vivior system. We are now ready to support eye care professionals in offering the
Quinbrook Infrastructure Partners Launches with Mercatus26.3.2019 16:00:00 EET | Tiedote
Mercatus, a leading alternative asset and investment management platform, today announced the initial launch of Quinbrook Infrastructure Partners with the Mercatus Investment Lifecycle Management (ILM) Platform. Quinbrook invests in a wide range of low carbon and renewable energy infrastructure assets spanning onshore wind, utility scale and distributed solar PV, battery storage, peaking capacity and ‘smart grids’. Quinbrook recently announced final close on its latest strategy securing over USD 1.6 billion from institutional investors to support ‘value add’ investments in the US, UK and Australian markets. The Mercatus Investment Lifecycle Management (ILM) Platform systematizes and centralizes asset, fund, and portfolio data to give investors accurate analytics and real-time performance, risk, and ESG insights. “Mercatus offered us the fastest time-to-value on our biggest need: streamlining how we work with our rapidly expanding stable of portfolio companies and preparing for the digi
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme